secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0001104659-24-051944
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Immunome appoints Dr. Sandra Swain as Class III director, joins Audit Committee
-------------------------------------------------------------------------------

- Appointment effective April 25, 2024; term expires at 2026 annual meeting.
- Annual cash retainer: $40,000 for Board, $7,500 for Audit Committee membership.
- Initial option grant of $270,000 Black-Scholes value, vesting quarterly over three years.
- Isaac Barchas stepped down from Audit Committee; new members: Schafer (Chair), Swain, Bienaimé.
- Dr. Swain also receives automatic annual option grants of $135,000 vesting over 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924051944/0001104659-24-051944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924051944/tm2412702d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-051944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer